

Dated: September 26, 2000.

**Nancy Cheal,**

*Acting Associate Director for Policy,  
Planning, and Evaluation, Centers for Disease  
Control and Prevention (CDC).*

[FR Doc. 00-25144 Filed 9-29-00; 8:45 am]

**BILLING CODE 4163-18-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### Statement of Organization, Functions, and Delegations of Authority

Part C (Centers for Disease Control and Prevention) of the Statement of Organization, Functions, and Delegations of Authority of the Department of Health and Human Services (45 FR 67772-76, dated October 14, 1980, and corrected at 45 FR 69296, October 20, 1980, as amended most recently at 65 FR 41079, dated July 3, 2000) is amended to reflect the retitling of the Division of Public Health Systems and the Division of Media and Training Services, Public Health Practice Program Office, to the Division of Public Health Systems Development

and Research and the Division of Professional Development and Evaluation respectively.

Section C-B, Organization and Functions, is hereby amended as follows:

Delete the title *Division of Public Health Systems (CH5)* and insert the title *Division of Public Health Systems Development and Research (CH5)*.

Delete the title *Division of Media and Training Services (CH7)* and insert the title *Division of Professional Development and Evaluation (CH7)*.

Dated: September 20, 2000.

**Martha Katz,**

*Acting Director.*

[FR Doc. 00-25261 Filed 9-29-00; 8:45 am]

**BILLING CODE 4160-18-M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. 00N-1516]

#### **Apothecon, Inc., et al.; Withdrawal of Approval of 76 Abbreviated New Drug Applications**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is withdrawing approval of 76 abbreviated new drug applications (ANDA's). The holders of the applications notified the agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.

**EFFECTIVE DATE:** October 10, 2000.

**FOR FURTHER INFORMATION CONTACT:**

Olivia A. Pritzlaff, Center for Drug Evaluation and Research (HFD-7), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-594-2041.

**SUPPLEMENTARY INFORMATION:** The holders of the applications listed in the table in this document have informed FDA that these drug products are no longer marketed and have requested that FDA withdraw approval of the applications. The applicants have also, by their request, waived their opportunity for a hearing.

ANDA No.	Drug	Applicant
60-100	Crysticillin (Penicillin G Procaine Suspension USP).	Apothecon, Inc., P.O. Box 4500, Princeton, NJ 08543.
60-618	Grifulvin V (Griseofluvin Microsize) Tablets, 125 milligrams (mg), 250 mg, and 500 mg.	Johnson & Johnson Consumer Co, Inc., 199 Grandview Rd., Skillman, NJ 08858.
61-220	Ophthochlor (Chloramphenicol Ophthalmic Solution USP) 5 mg/milliliter (mL).	Parkedale Pharmaceuticals, Inc., 501 Fifth St., Bristol, TN 37620.
61-334	Bactocill (Oxacillin Sodium for Injection).	SmithKline Beecham Pharmaceuticals, One Franklin Plaza, P.O. Box 7929, Philadelphia, PA 19101.
61-449	Staphcillin (Methicillin Sodium).	Apothecon, Inc.
61-452	Cloxacillin Sodium Capsules USP, 250 mg and 500 mg.	Do.
61-739	Garamycin Pediatric Injection (Gentamicin Sulfate Injection USP).	Schering Corp., 2000 Galloping Hill Rd., Kenilworth, NJ 07033.
62-328	Erythromycin Topical Solution USP, 1.5%.	Alpharma, 333 Cassell Dr., suite 3500, Baltimore, MD 21224.
62-727	Totacillin-N (Ampicillin Sodium) for Injection.	Smithkline Beecham Pharmaceuticals.
62-755	Nalpen (Nafcillin Sodium Powder for Injection USP).	Do.
70-356	Diazepam Tablets USP, 2 mg.	Roxane Laboratories, Inc., P.O. Box 16532, Columbus, OH 43216.
70-357	Diazepam Tablets USP, 5 mg.	Do.
70-358	Diazepam Tablets USP, 10 mg.	Do.
71-010	Acetaminophen Suppositories, 120 mg.	Do.
71-011	Acetaminophen Suppositories, 650 mg.	Do.
71-018	Metaproterenol Sulfate Inhalation Solution USP, 0.6%.	AstraZeneca, L.P.
71-275	Metaproterenol Sulfate Inhalation Solution USP, 0.4%.	Do.
72-018	Droperidol Injection USP, 2.5 mg/mL.	Do.
72-019	Droperidol Injection USP, 2.5 mg/mL.	Do.
72-021	Droperidol Injection USP, 2.5 mg/mL.	Do.
72-648	Timolol Maleate Tablets USP, 5 mg.	Novopharm Limited, c/o Novopharm NC, Inc., 4700 Novopharm Blvd., Wilson, NC 27893.
72-649	Timolol Maleate Tablets USP, 10 mg.	Do.
72-650	Timolol Maleate Tablets USP, 20 mg.	Do.